Myesha Edwards - Global Blood IR Contact Officer
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Executive
Myesha Edwards is IR Contact Officer of Global Blood Therapeutics since 2016.
| Tenure | 8 years |
| Phone | 650 741-7700 |
| Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chiaka Berthe | Barrick Gold Corp | 48 | |
| John Steele | Barrick Gold Corp | 59 | |
| Williem Jacobs | Barrick Gold Corp | 58 | |
| Joel Holliday | Barrick Gold Corp | N/A | |
| Poupak Bahamin | Barrick Gold Corp | 53 | |
| Victor Matfield | Barrick Gold Corp | N/A | |
| Lois Wark | Barrick Gold Corp | 68 | |
| Matthew CFA | HNI Corp | N/A | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| Grant Beringer | Barrick Gold Corp | 43 | |
| Ngolo Sanogo | Barrick Gold Corp | N/A | |
| Tania Welzim | Barrick Gold Corp | N/A | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Riaan Grobler | Barrick Gold Corp | N/A | |
| Samba Toure | Barrick Gold Corp | 59 | |
| Kathy Sipos | Barrick Gold Corp | 49 | |
| Sebastiaan Bock | Barrick Gold Corp | 45 | |
| Tahirou Ballo | Barrick Gold Corp | N/A | |
| Philip Pretorius | Barrick Gold Corp | N/A | |
| Rodney Quick | Barrick Gold Corp | 48 | |
| Adama Kone | Barrick Gold Corp | 57 | |
Management Performance
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
| Michael Bonney, Director | ||
| Stephanie Yao, IR Contact Officer | ||
| Myesha Lacy, IR Contact Officer | ||
| Mark Perry, Independent Director | ||
| Jeffrey Farrow, CFO | ||
| Myesha Edwards, IR Contact Officer | ||
| Philip Pizzo, Director | ||
| Glenn Pierce, Director | ||
| Willie Brown, Independent Director | ||
| Wendy Yarno, Director | ||
| Kevin Starr, Director | ||
| Hing Sham, Senior Vice President - Chemistry | ||
| Scott Morrison, Director | ||
| Deval Patrick, Independent Director | ||
| Tricia Suvari, Chief Legal Officer | ||
| Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
| David Johnson, Chief Commercial Officer | ||
| Charles Homcy, Director | ||
| Dawn Svoronos, Director | ||
| Ted Love, President CEO, Director | ||
| Eleanor Ramos, Chief Medical Officer | ||
| John Schembri, Vice President of Finance and Administration | ||
| Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |